

ASX RELEASE

17 November 2017

KAZIA THERAPEUTICS - TICKER UPDATE

Sydney, 17 November 2017 – Following the announcement earlier today, the ASX has advised that the Company will not trade under the new ticker of KZA until 29 November 2017, once the share consolidation has been completed. The Company will trade under the following tickers until that time:

- From 17 November: ordinary shares as NRTDA, options as NRTDB
- On 28 November: ordinary shares as NRT, options as NRTO
- From 29 November: ordinary shares as KZA, options as KZAO

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, formerly Novogen Limited (ASX: KZA, NASDAQ: KZIA) is an agile oncology-focused biotechnology company, based in Sydney, Australia. We have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017.

TRXE-002-1, or Cantrixil is Kazia's second drug development candidate under development as a treatment for ovarian cancer. The chemotherapeutic is currently undergoing a Phase I clinical trial in hospitals across Australia and the United States. Initial data on this trial is expected to be reported early in 2018.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director